Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Head-to-head comparison of dupilumab vs mepolizumab in chronic rhinosinusitis with nasal polyps
2022-502250-14-00Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Dupixent arm with Nucala arm (2 arms). Primary endpoints: Change in nasal polyp score at 24 weeks and Change in SNOT-22 score at 24 weeks. Started Mar 2023; status: completed.
02
Drugs
dupilumabmepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2022-502250-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502250-14-00.